版本:
中国

BRIEF-RedHill Biopharma confirms initiation of late-stage study on its stomach infection drug

June 15 RedHill Biopharma Ltd-

* RedHill biopharma announces confirmatory phase III study initiated with rhb-105 (talicia™) for H. Pylori infection

* RedHill Biopharma Ltd - confirmatory phase III study (eradicate hp 2) is expected to complete package required for a potential U.S. Nda for rhb-105 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐